A Randomized Trial Comparing the Speci fi c Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn ’ s Disease

Charlene W. Compher,A. Dobes,Colleen M. Brensinger,Ellen Scherl,Kimberly Braly,M. Kappelman,A. Saxena,Sara N. Horst,Sumona Saha,Robert S. Sandler,Jeffrey R. Curtis,Ann D. Flynn,A. Swaminath,L. McKeever,Hongzhe Li,Scott G. Daniel,James D. Lewis,M. Bewtra,Kyle Bittinger,Bruce Yacyshyn,M. McCauley,L. Albenberg,John F. Valentine,L. Nessel,Andrea Meyer,D. Suskind,C. Brotherton,Benjamin L. Cohen,John S. Hanson,Monika Fischer
Abstract:week 6 included fecal calprotectin (FC) response (FC < 250 m g/g and reduction by > 50% among those with baseline FC > 250 m g/g) and C-reactive protein (CRP) response (high-sensitivity CRP < 5 mg/L and > 50% reduction from baseline among those with high-sensitivity CRP > 5 mg/L). RESULTS: The study randomized 194 patients, and 191 were included in the ef fi cacy analyses. The percentage of participants who achieved symptomatic remission at week 6 was not superior with the SCD (SCD, 46.5%; MD, 43.5%; P ¼ .77). FC response was achieved in 8 of 23 participants (34.8%) with the SCD and in 4 of 13 participants (30.8%) with the MD ( P ¼ .83). CRP response was achieved in 2 of 37 participants (5.4%) with the SCD and in 1 of 28 participants (3.6%) with the MD ( P ¼ .68). CONCLUSIONS: The SCD was not superior to the MD to achieve symptomatic remission, FC response, and CRP response. CRP response was uncommon. Given these results, the greater ease of following the MD and other health bene fi ts associated with the MD, the MD may be preferred to the SCD for most patients with CD with mild to moderate symptoms. ClinicalTrials.gov Identi fi er: NCT03058679
Medicine
What problem does this paper attempt to address?